Skip to main content
Premium Trial:

Request an Annual Quote

Oxford BioDynamics EpiSwitch CIRT

Oxford BioDynamics has launched EpiSwitch CIRT, its checkpoint inhibitor response test, in the US. The blood-based test, which is based on the firm's EpiSwitch 3D genomics platform, is for predicting patient response to immune checkpoint inhibitors, including anti-PD-L1 and anti-PD-1 immunotherapies. According to the company, the qPCR test has demonstrated 93 percent sensitivity and 82 percent specificity across several immune checkpoint inhibitors from several drug firms and more than 15 oncological indications.